Trius Announces Issuance of Tedizolid Patent in China

Trius Therapeutics, Inc.

announced today the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to the issuance in China, patents for tedizolid phosphate have also issued in other jurisdictions including Australia, Canada, Europe, India, Japan, Mexico, Russia and the United States. Trius licensed the rights to tedizolid phosphate for Asia-Pacific and emerging markets to Bayer Pharmaceuticals and recently announced receiving a $5 million milestone payment from Bayer after the successful completion of the "112" Phase 3 clinical study of tedizolid phosphate in acute bacterial skin and skin structure infections (ABSSSI). Trius retains the rights to tedizolid in the U.S., Canada and the EU countries.